3,375
Views
8
CrossRef citations to date
0
Altmetric
Clinical Study

Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials

, , , , , , , , & show all
Pages 671-679 | Received 19 Jun 2018, Accepted 02 Oct 2018, Published online: 03 Dec 2018
 

Abstract

Background: Anemia is extremely common among dialysis patients and underlies some of the symptoms associated with reduced kidney function, including fatigue, depression, reduced exercise tolerance, and dyspnea.

Objectives: A clearer cognition of the prognosistic impact of hemoglobin (Hb) or hematocrit (Hct) target for the outcomes of dialysis patients is urgent. This article aims to establish the suitable hemoglobin in order to provide clinical guidance.

Methods: MEDLINE, EmBase, the Cochrane Library and other databases were searched with both MeSH terms and keywords to gather randomized controlled trials that assessed all-cause mortality, cardiovascular events, fistula thrombosis, infectious diseases and transfusion among dialysis-dependent patients using erythropoiesis-stimulating agents. The meta-analysis was accomplished via Revman 5.3 version.

Findings: Totally, nine eligible studies were included, with study subjects involving 3228 patients. There was a significantly higher risk of fistula thrombosis without heterogeneity (RR 1.34, 95% CI 1.15–1.55; p < 0.05) in the higher Hb target group than in the lower Hb target group in the fixed effects model. However, no significant difference was found in all-cause mortality in the fixed effects model (RR 1.09, 95% CI 0.93–1.27; p = 0.30), cardiovascular events (RR 0.77, 95% CI 0.31–1.92; p = 0.58), infectious diseases (RR 0.69, 95% CI 0.24–1.96; p = 0.49) and transfusion (RR 0.92, 95% CI 0.42–1.99; p = 0.82) in the random effects model between the higher Hb target group and the lower Hb target group.

Discussion: The results favor lower Hb target. To target lower Hb target when treating dialysis patients with anemia may decrease the risk of fistula thrombosis without increasing the risk of death, cardiovascular events, infectious diseases and transfusion.

Acknowledgments

We wish to thank Shaomin Li for his revision of the English manuscript.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This study was supported by the National Natural Science Foundation of China [Grant No. 81370866 and Grant No. 81070612], the China Postdoctoral Science Foundation [Grant No. 201104335], the Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program [Grant No. YHJH201806], the Fundamental Research Funds for the Central Universities [Grant No. 11ykpy38] and the National Project of Scientific and Technical Supporting Programs Funded by Ministry of Science & Technology of China [Grant No. 2011BAI10B00].